Press releases
STORM Therapeutics’ will be attending the following virtual conferences.
Read more
STC-15, the first-in-class drug candidate targeting METTL3, has been selected for development towards first in human clinical studies.
Read more
Presentations will showcase the activity of first-in-class METTL3 inhibitors in a range of solid tumours, building on prior POC data in AML. Establishes new therapeutic opportunities for METTL3 inhibitors across a wide range of solid cancers
Read more
Dr. Holz has over 25 years’ experience in pharmaceutical drug development in Europe and North America.
Read more
Dr. Lauder has over 15 years of business development experience working with biotech and pharmaceutical companies, and academia.
Read more